Oxford BioDynamics (GB:OBD) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Oxford BioDynamics Plc has reported continued growth in its biotechnology segment with an emphasis on the commercialization of its EpiSwitch tests, observing a revenue increase and expanding market presence through various commercial agreements. Despite an operating loss, the company has successfully secured funding to support near-term plans and has advanced its test offerings, including securing US reimbursement for its EpiSwitch PSE test and partnering with health providers for broader access.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.